Treatment Factors That Influence Mortality in Acromegaly

被引：27

作者：

McCabe, John ^{[1
]}

Ayuk, John ^{[3
]}

Sherlock, Mark ^{[1
,2
]}

机构：

[1] Natl Childrens Hosp, Adelaide & Meath Hosp, Dept Endocrinol, Tallaght, Ireland

[2] Univ Dublin Trinity Coll, Dept Endocrinol, Dublin 2, Ireland

[3] Queen Elizabeth Hosp, Dept Endocrinol, Birmingham B15 2TH, W Midlands, England

来源：

NEUROENDOCRINOLOGY | 2016年 / 103卷 / 01期

关键词：

Acromegaly; Mortality; Treatment; Growth hormone; Insulin-like growth factor-I; Radiotherapy; Hypopituitarism; GROWTH-FACTOR-I; SOMATOSTATIN ANALOG THERAPY; COLONIC POLYPS; INCREASED PREVALENCE; PITUITARY-ADENOMAS; TRANSSPHENOIDAL MICROSURGERY; COLORECTAL NEOPLASIA; EXCESS MORTALITY; PREDICTIVE-VALUE; META-ANALYSIS;

D O I：

10.1159/000375163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Acromegaly is a rare condition characterized by excessive secretion of growth hormone (GH), which is almost always due to a pituitary adenoma. Acromegaly is associated with significant morbidity such as hypertension, type 2 diabetes, cardiomyopathy, obstructive sleep apnoea, malignancy and musculoskeletal abnormalities. Acromegaly has also been associated with increased mortality in several retrospective studies. This review will focus on the epidemiological data relating to mortality rates in acromegaly, the relationship between acromegaly and malignancy, the role of GH and insulin-like growth factor-I in assessing the risk of future mortality, and the impact of radiotherapy and hypopituitarism on mortality. (C) 2015 S. Karger AG, Basel

引用

页码：66 / 74

页数：9

共 85 条

[1] Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results [J].

Abosch, A ;

Tyrrell, JB ;

Lamborn, KR ;

Hannegan, LT ;

Applebury, CB ;

Wilson, CB .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3411-3418

[2] EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION [J].

ALEXANDER, L ;

APPLETON, D ;

HALL, R ;

ROSS, WM ;

WILKINSON, R .

CLINICAL ENDOCRINOLOGY, 1980, 12 (01) :71-79

[3] Mortality in 154 surgically treated patients with acromegaly - A 10-year follow-up survey [J].

Arita, K ;

Kurisu, K ;

Tominaga, A ;

Eguchi, K ;

Iida, K ;

Uozumi, T ;

Kasagi, F .

ENDOCRINE JOURNAL, 2003, 50 (02) :163-172

[4] Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly [J].

Ayuk, J ;

Clayton, RN ;

Holder, G ;

Sheppard, MC ;

Stewart, PM ;

Bates, AS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (04) :1613-1617

[5] Acromegaly and cancer risk: a cohort study in Sweden and Denmark [J].

Baris, D ;

Gridley, G ;

Ron, E ;

Weiderpass, E ;

Mellemkjaer, L ;

Ekbom, A ;

Olsen, JH ;

Baron, JA ;

Fraumeni, JF .

CANCER CAUSES & CONTROL, 2002, 13 (05) :395-400

[6]

BATES AS, 1993, Q J MED, V86, P293

[7] Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly [J].

Beauregard, C ;

Truong, U ;

Hardy, J ;

Serri, O .

CLINICAL ENDOCRINOLOGY, 2003, 58 (01) :86-91

[8]

BENGTSSON BA, 1988, ACTA MED SCAND, V223, P327

[9] Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly [J].

Bevan, JS .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (03) :1856-1863

[10] Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements [J].

Biermasz, NR ;

Dekker, FW ;

Pereira, AM ;

van Thiel, SW ;

Schutte, PJ ;

van Dulken, H ;

Romijn, JA ;

Roelfsema, F .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2789-2796

← 1 2 3 4 5 6 7 8 9 →